Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks
Phase of Trial: Phase II
Latest Information Update: 07 May 2018
At a glance
- Drugs ORM 12741 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms NEBULA
- Sponsors Orion
- 07 Feb 2018 Status changed from active, no longer recruiting to completed according to the Orion media release.
- 13 Jan 2018 This trial has been completed in Bulgaria (End date: 2017-10-09), according to European Clinical Trials Database.
- 19 Dec 2017 This trial was completed in Bulgaria (end date: 2017-10-09), according to European Clinical Trials Database.